AM285 demonstrates anticancer activity in combination with conventional agents.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000037:antagonists & inhibitors*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology
D015507:Drugs, Investigational; D003402:Creatine Kinase